Adlai Nortye(ANL) Newsfilter·2024-05-24 01:03Core Viewpoint - Adlai Nortye Ltd. is set to present promising preliminary data on its drug AN0025 in combination with definitive chemoradiotherapy for treating unresectable locally advanced or locally recurrent esophageal cancer at the ASCO Annual Meeting in Chicago from May 31 to June 4, 2024 [1][3]. Company Overview - Adlai Nortye Ltd. is a clinical-stage biotechnology company focused on developing innovative cancer therapies, with R&D centers in New Jersey, US, and Hangzhou, China [4]. - The company has a robust pipeline of six drug candidates aimed at addressing various tumor types [4]. - Adlai Nortye aims to become a global leader in oncology therapies through a combination therapy strategy, with the goal of transforming deadly cancers into chronic and eventually curable diseases [5]. Clinical Study Details - AN0025 is a selective EP4 inhibitor that modulates macrophages and immunosuppressive myeloid cells in the tumor microenvironment, showing antitumor activity [2]. - The AN0025S0104 study is a Phase Ib clinical trial designed to evaluate the safety, tolerability, and feasibility of AN0025 combined with definitive chemoradiotherapy for esophageal cancer [2]. - The study is a single-arm, open-label, multicenter trial that includes a dose escalation phase followed by an expansion phase [2]. Upcoming Presentation - The abstract for the ASCO presentation is titled "AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): a single-arm, open-label, multicenter, Phase Ib study (AN0025S0104)" [3]. - The first author of the abstract is Nan Bi from the Department of Radiation Oncology, National Cancer Center, Chinese Academy of Medical Sciences [3].